High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study

Silvia Bressan · Marco Balzani · Baruch Krauss · Andrea Pettenazzo · Stefania Zanconato · Eugenio Baraldi

Abstract High-flow nasal cannula (HFNC) is a widely used ventilatory support in children with bronchiolitis in the intensive care setting. No data is available on HFNC use in the general pediatric ward. The aim of this study was to evaluate the feasibility of HFNC oxygen therapy in infants hospitalized in a pediatric ward for moderate–severe bronchiolitis and to assess the changes in ventilatory parameters before and after starting HFNC support. This prospective observational pilot study was carried out during the bronchiolitis season 2011–2012 in a pediatric tertiary care academic center in Italy. Interruptions of HFNC therapy and possible side effects or escalation to other forms of respiratory support were recorded. Oxygen saturation (SpO2), end-tidal carbon dioxide (ETCO2), and respiratory rate (RR), measured for a baseline period of 1 h before and at specific time intervals in 48 h after the start of HFNC were recorded. Twenty-seven infants were included (median age 1.3 months; absolute range 0.3–8.5). No adverse events, no premature HFNC therapy termination, and no escalation to other forms of respiratory support were recorded. Median SpO2 significantly increased by 1–2 points after changing from standard oxygen to HFNC ($p < 0.001$). Median ETCO2 and RR rapidly decreased by 6–8 mmHg and 13–20 breaths per minute, respectively, in the first 3 h of HFNC therapy ($p <0.001$) and remained steady thereafter. Conclusions: Use of HFNC for oxygen administration is feasible for infants with moderate–severe bronchiolitis in a general pediatric ward. In these children, HFNC therapy improves oxygen saturation levels and seems to be associated with a decrease in both ETCO2 and RR.

Keywords Bronchiolitis · Oxygen inhalation therapy · Children · Carbon dioxide

Abbreviations
ETCO2 End-tidal carbon dioxide
FiO2 Fraction of inspired oxygen
HFNC High-flow nasal cannula
HR Heart rate
PICU Pediatric intensive care unit
RR Respiratory rate
RSV Respiratory sincitial virus
SpO2 Oxygen saturation

Introduction

Bronchiolitis is the most common lower respiratory tract infection in the first year of life and the leading cause of hospitalization in infants [3, 33]. Despite the growing literature investigating treatment options with recent positive data about the use of nebulized hypertonic saline and epinephrine [11, 32], oxygen supplementation still remains the mainstay of therapy [19].

Oxygen therapy administered by heated, humidified high-flow nasal cannulae (HFNC) has been shown to reduce the intubation rate and to improve respiratory distress in children hospitalized in intensive care units for bronchiolitis [19, 22]. HFNC has proven to be a well tolerated, non-invasive respiratory support which provides a humidified and heated air-oxygen blend at a flow of 1 to 8 l/min [19, 22]. HFNC are thought to improve the ventilatory status by prevention of
mucous dryness and improvement of mucous-ciliary clearance, reduction of energy expenditure for gas warming and humidification, and provision of continuous positive airway pressure, which contributes to the maintenance of patent alveoli, improves the ventilation–perfusion mismatch, and prevents microatelectasis [6, 9, 12].

The advantages of HFNC over nasal continuous positive airways pressure, i.e., its ease of use and improved tolerance with minimal nasal trauma, have led to increasing utilization also outside the intensive care unit [10, 17, 30]. However, there is a current lack of data on the feasibility of HFNC in infants with bronchiolitis managed on the pediatric ward and its effects on ventilation status have not been thoroughly investigated. HFNC oxygen therapy has been introduced as a standard of care at our institution for use in patients with bronchiolitis admitted to the general pediatric ward since September 2011. This decision was based on local expert consensus. The aim of this study was to evaluate the feasibility of oxygen therapy administered via HFNC in infants hospitalized for moderate–severe bronchiolitis in a regular pediatric ward and to assess the changes in ventilatory parameters before and after starting HFNC support.

Methods

Study design and setting

A prospective observational pilot study of admitted infants with moderate–severe bronchiolitis who received HFNC oxygen therapy on a pediatric ward at the University of Padova Hospital (Italy), from November 2011 to April 2012. Our Pediatric Department is provided with a pediatric intensive care unit (PICU) and a rapid admission process for deteriorating in-patients. Education on HFNC use was provided to medical and nursing staff working in the general pediatric ward by means of a dedicated half-day course, including lectures and practice (i.e., hands-on session on how to assemble the HFNC device and disposable materials, how to provide good equipment maintenance, and to monitor good functioning). After the course, a dedicated procedure on HFNC use was also available in the quality system of the hospital intranet (IO-PED2-007). A trained member of the respiratory team was readily available in case of any problem related to HFNC use.

Definitions

Bronchiolitis was defined as the first viral episode of respiratory distress, accompanied by coryza, cough, crepitations, and/or wheezing [23]. Day of disease was counted from date of onset of respiratory symptoms (rhinorrhea, cough, respiratory distress) as reported by parents.

Inclusion and exclusion criteria

Neonates and infants aged 7 days to 12 months who were hospitalized for their first episode of moderate–severe bronchiolitis and required oxygen therapy were enrolled in the study. Exclusion criteria included recurrent wheezing, underlying hemodynamically significant heart disease, chronic lung disease, neuromuscular disease, oxygen therapy at home, and tracheostomy.

Clinical evaluation and management

Bronchiolitis severity was assessed according to our emergency department bronchiolitis protocol using a score adapted from Wang et al. [28] (see Appendix). Moderate bronchiolitis was defined by a score of >5 and severe by a score of >10. According to the protocol, children with moderate and severe bronchiolitis received oxygen therapy with nebulized 3 % hypertonic saline when presenting an oxygen saturation (\(\text{SpO}_2\)) <92 %, i.e., with 2 or 3 points on the item “oxygen saturation” of the severity score (see Appendix). Only children with moderate–severe bronchiolitis needing oxygen supplementation according to the emergency department protocol were included in the study.

Hypertonic saline was introduced as a standard of care in our emergency department since 2010 for patients with moderate–severe bronchiolitis who needed oxygen supplementation, based on local expert consensus and available evidence [18]. A trial of nebulized salbutamol was given if audible wheezing was present. Children with severe bronchiolitis received oxygen therapy and nebulized epinephrine 0.25 mg/kg in 3 % hypertonic saline. In the emergency department, standard oxygen therapy, up to 2 l/min through regular nasal cannula, was administered. HFNC oxygen therapy was started once infants were admitted to the ward.

Feasibility evaluation

Unanticipated interruptions of HFNC oxygen therapy due to difficulties in management of the device or patient intolerance to nasal cannulae, as reported either by nurses or medical staff, were recorded. Side effects to HFNC use, such as nasal mucosa trauma and/or bleeding, vomiting (as a possible result of gastric distension), and pneumothorax, as well as the need for escalation to other forms of respiratory support, were monitored and recorded. All this data was collected in a dedicated checklist form that was reviewed during the daily ward rounds and was then entered into the electronic database along with patients’ data that were collected in the clinical report form.

Vital signs recording

Oxygen saturation, respiratory rate (RR), heart rate (HR), body temperature, and end-tidal carbon dioxide (ETCO\(_2\)
were recorded for each patient for a baseline period of 1 h (t-1 and t0) before HFNC positioning. Oxygen saturation at baseline (t-1 and t0) was recorded with standard oxygen and at room air. The same parameters were then recorded at 1 h (t1), 3 h (t3), 6 h (t6), 12 h (t12), 24 h (t24), 36 h (t36), and 48 h (t48) after the start of HFNC. A nasopharyngeal aspirate for viral detection through real time PCR was performed in all infants. Additional tests were undertaken according to the treating physician.

Instrumentation and devices

*Vital signs monitor*

SpO2 and HR were recorded using the Monitor Agilent M3046A-Philips; RR was manually measured counting the breaths per minute.

*ETCO2*

End-tidal CO2 was monitored using nasal cannulae (Philips CapnoLine H Infant/Neonatal) specific for infants less than 10 kg [5] and connected to the Monitor Agilent M3046A-Philips. Nasal cannulae for oxygen administration were removed for the time required for the ETCO2 measurement. Capnography was monitored for 1 min, during which, time values were recorded every 10 s. The final ETCO2 values used for data analysis were the mean of all six recordings (every 10 s for a minute).

*HFNC*

The Fisher & Paykel Healthcare heated humidified HFNC system (MR850 humidification system, RT329 Kit and Optiflow oxygen cannulas; Fisher & Paykel Healthcare, Auckland, New Zealand) was used in all patients. The low-resistance nasal cannulae (Fisher and Paykel Healthcare) included an intermediate cannula BC 2755 base diameter 3.4±0.77 mm, tip diameter 2.7±0.56 mm, with a maximum flow rate of 7 l/min and a pediatric cannula BC 7380 base diameter 4.6±0.7 mm, tip diameter 4.25±0.75 mm, with a maximum flow rate of 8 l/min. The size of the cannulas fitted the child’s nares without occlusion. The flow rate was determined using a derived formula [27]: flow rate (in liters per minute) = weight (in kilograms)+1, with a maximum flow rate of 8 l/min and a constant flow temperature of 37 °C. This choice was made in order to deliver a flow greater than the patient minute ventilation, so that effective fraction of inspired oxygen (FiO₂) equals the nasal cannula oxygen concentration by preventing mixing with room air, and to minimize possible adverse events related to delivery of inadvertently too high positive end expiratory pressure for the patient. The system has an integrated pressure relief valve (manifold) at its input port to limit the maximum system pressure. This valve is set at 45-cm H₂O.

The inspired oxygen concentration was adjusted to achieve a SpO2 ≥94 %. Flow rate was weaned by 1 l/min every 6 h when adequate oxygen saturations were maintained with a FiO₂ of 25 %. HFNC was stopped and switched to standard oxygen therapy, if necessary, once the patients remained stable with a flow of 2 l/min.

Statistical analysis

Continuous variables were expressed as medians and absolute ranges. The overall comparison of repeated measures over time was carried out by means of Friedman test (two-way analysis of variance by ranks). Comparisons between each measure at baseline (t-1 and t0) and each time point after initiation of HFNC were then carried out by means of Wilcoxon test for paired samples. Categorical variables were expressed as numbers and percentages. Parameters displaying \(p<0.05\) were considered statistically significant. Statistical analyses were conducted using the statistical program MedCalc 11.1.

The study was reviewed and approved by the Hospital Ethics Committee, approval number 2476P, and informed consent was obtained from the parents or legal guardians.

*Results*

Of the 80 infants less than 1 year of age hospitalized for bronchiolitis during the study period, 42 were not eligible because of mild bronchiolitis (clinical score ≤5). Thirty-eight patients presented a moderate–severe bronchiolitis and 27 were finally enrolled (Fig. 1).

Demographic and clinical characteristics of study patients are reported in Table 1. Twenty-two patients were under 3 months of age. Nineteen patients were hospitalized between December and January.

There were no cases of unanticipated interruptions of HFNC oxygen administration and the therapy was well tolerated by all study patients with no need for sedation. There were no cases of pneumothorax or any other reported adverse events. None of the study patients were admitted to the intensive care unit because of the need of escalation to other forms of respiratory support.

After changing from standard oxygen to HFNC, SpO2 showed a statistically significant increase—Table 2. Median FiO₂ administered to achieve target saturation was 40 % (as set in the device) in the first 12 h and slightly reduced thereafter—Table 2. The comparison between repeated measurements of ETCO2 and RR over time resulted significantly different as per Friedman test \(p<0.001\). Median ETCO2 and RR decreased after initiation of HFNC at all time...
intervals ($p < 0.001$ for each comparison between the baseline period (t-1, t0) and during HFNC therapy, (t1–t48))—Table 2, Figs. 2 and 3. No difference was observed in the time course of HR values.

**Discussion**

In this pilot study, we describe the use of oxygen therapy delivered via HFNC in infants hospitalized for moderate–severe bronchiolitis in a pediatric ward and its effects on ventilatory parameters. Our results show that HFNC oxygen therapy is a feasible delivery system for oxygen administration in a pediatric ward. It provides optimal oxygen saturation levels and is associated with a decrease in both ETCO$_2$ and RR.

Effective non-invasive respiratory support in children with moderate–severe bronchiolitis is important in order to improve comfort by reducing work of breathing, and to prevent complications such as atelectasis as well as progressive respiratory exhaustion which may lead to respiratory failure. HFNC respiratory support has been well-tolerated with few adverse effects in both children [13, 19, 22] and pre-term neonates [6] in pediatric and neonatal intensive care units. In pre-term infants, HFNC have mainly been evaluated for the treatment of apnea of prematurity [25], respiratory distress syndrome, and the prevention of extubation failure [4, 15, 24, 31]. However, its effectiveness compared to traditional nasal-CPAP has not been rigorously studied [6, 7, 29].

The increasing availability of HFNC devices in the intensive care setting over the past few years, as well as its tolerance and ease of use, has prompted use in other respiratory diseases such as bronchiolitis. The first studies assessing the usefulness of HFNC in children with bronchiolitis were carried out in PICU in the United States and Australia [19, 22]. McKiernan et al. [19] retrospectively studied 115 children (57 from before the introduction of HFNC and 58 from the season after the introduction of HFNC) and showed a $68\%$ decrease in intubations and a decrease in the median PICU length of stay from 6 to 4 days after the introduction of HFNC. Australian investigators noted a decline in intubation rate from 37 to 7 %, with no adverse events, in a retrospective chart review over a 5-year period of 167 children with bronchiolitis treated with HFNC in the PICU [21]. Similar to our results, both studies found a reduction in respiratory rate at 60 [19] and 90 min [22] after initiation of HFNC therapy.

A randomized controlled trial [14] of 19 infants with bronchiolitis showed a higher median SpO$_2$ in patients

| Variable | Results |
|----------|---------|
| Age in months (median, range) | 1.3 (0.3–8.5) |
| Age <6 months ($n$) | 24 |
| History of Prematurity | |
| 32–36 wg ($n$) | 4 |
| 28–32 wg ($n$) | 2 |
| Sex (female/male) | 13/14 |
| Weight in Kg (median, range) | 4.2 (2.6–7.2) |
| Day of illness at hospitalization (median, range) | 2 (1–8) |
| Clinical Score at t0 ($n$) | |
| 6–10 | 23 |
| >10 | 4 |
| Viral status ($n$) | |
| RSV | 14 |
| RSV—Rhinovirus | 7 |
| RSV—Coronavirus | 1 |
| RSV—Rhinovirus—Coronavirus | 1 |
| Adenovirus—Bocavirus—Rhinovirus | 2 |
| Unknown | 2 |
| Chest x-rays performed ($n$) | 22 |
| Major abnormality on chest x-rays ($n$) | 3* |
| Nebulized therapy prior to HFNC | |
| 3 % hypertonic saline ($n$) | 27 |
| Salbutamol ($n$) | 20 |
| Epinephrine ($n$) | 4 |
| Intravenous fluid replacement therapy ($\geq$24 h) ($n$) | 25 |
| Duration of HFNC (days) (median, range) | 5 (3–14) |
| Length of hospitalization (days) (median, range) | 8 (4–15) |

*1 lobar atelectasis and 2 lobar consolidations. Major abnormalities on the chest x-rays for the purpose of this study were defined as: lobar atelectasis, lobar consolidations, or pneumothorax.

---

**Table 1 Clinical and demographic characteristics of study patients**

**Fig. 1 Patients flow-chart. HFNC high-flow nasal cannulae; HS hemodynamically significant; BPD bronchopulmonary dysplasia**
receiving HFNC oxygen therapy compared with head-box oxygen at 8 h (100 vs. 96 %, p = 0.04) and 12 h (99 vs. 96 %, p = 0.04). Total time in oxygen, time to feed, time to discharge, and total length of stay, were similar between groups. As acknowledged by the authors, the study was limited by the small sample size, the non-blinded intervention, and the lack of any formal measure of pulmonary mechanics or gas exchange other than SpO2. While the same authors express concern about the possibility that HFNC therapy with high concentrations of oxygen may provide falsely reassuring oxygenation in sick infants who are, in fact, tiring, our study shows that HFNC offers some ventilatory support as well, as reflected by the steady decrease in ETCO2 and RR after

![Fig. 2](image1.png)

**Fig. 2** ETCO2 values distribution over time pre- (baseline) and during HFNC therapy. The box-whisker plots show the median (horizontal line), the interquartile range (margins of box), the absolute range (vertical line) and outlier values (circle). ETCO2 end-tidal CO2; HFNC high-flow nasal cannulae

| Parameters | t-1 | t 0 | t 1 | t 3 | t 6 | t 12 | t 24 | t 36 | t 48 |
|------------|-----|-----|-----|-----|-----|------|------|------|------|
| ETCO2, mmHg | 36 (27–50) | 37 (27–50) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) |
| RR, breaths per minute | 67 (35–90) | 67 (35–90) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) |
| HR, beats per minute | 147 (120–170) | 147 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) |
| Sat O2, % | 89 (82–96) | 89 (82–96) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) |
| FiO2, % | 21 | 21 | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) |
| Fever >37.5 °C (% of infants) | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |

Paired comparisons were performed between values at t-1 and t0 with values at each time point after the start of HFNC therapy (t1–t48). Data are reported as medians and absolute ranges for each comparison.

ETCO2 p ≤ 0.001 for each comparison;
RR p ≤ 0.001 for each comparison;
SpO2 p = 0.001 for each comparison between values recorded in room air at baseline (¶) and during regular nasal cannulae delivered oxygen.

![Fig. 3](image2.png)

**Fig. 3** RR values distribution over time pre- (baseline) and during HFNC therapy. The box-whisker plots show the median (horizontal line), the interquartile range (margins of box), the absolute range (vertical line) and outlier values (circles). RR respiratory rate in breaths per minute (bpm); HFNC high-flow nasal cannulae

Table 2

| Parameters | t-1 | t 0 | t 1 | t 3 | t 6 | t 12 | t 24 | t 36 | t 48 |
|------------|-----|-----|-----|-----|-----|------|------|------|------|
| ETCO2, mmHg | 36 (27–50) | 37 (27–50) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) | 30 (20–42) |
| RR, breaths per minute | 67 (35–90) | 67 (35–90) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) | 50 (30–80) |
| HR, beats per minute | 147 (120–170) | 147 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) | 140 (120–170) |
| Sat O2, % | 89 (82–96) | 89 (82–96) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) | 85 (81–99) |
| FiO2, % | 21 | 21 | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) | 40 (25–60) |
| Fever >37.5 °C (% of infants) | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
initiation of HFNC oxygen delivery. None of our children needed escalation to other forms of respiratory support suggesting that the decrease in ETCO₂ and RR may identify responders to therapy. In the study by Shibler et al. [22], responders to HFNC showed a 20 % decrease in RR within 90 min of the start of HFNC therapy, whereas non-responders showed little change in RR. ETCO₂, however, was not measured.

A more recent study carried out in PICU has shown a decrease in RR in infants with bronchiolitis who responded to HFNC therapy, compared with the nonresponder group [1]. The same authors reported a decrease in PCO₂ on blood gas analysis, with significantly higher initial PCO₂ values in the nonresponder patients [1].

Measurement of ETCO₂ with capnography is a non-invasive indirect measurement of blood CO₂ tension with fast response time to changes in blood levels. It allows for visual inspection of changes in CO₂ concentrations by means of a waveform display. The principal determinants of ETCO₂ are alveolar ventilation, pulmonary perfusion (cardiac output), and metabolic status [16]. The present study is the first to evaluate the effect of HFNC therapy on gas exchange by means of ETCO₂ measurement in patients with bronchiolitis. Despite arterial blood gas analysis being the gold standard of monitoring partial pressure of arterial carbon dioxide, this is an invasive procedure and it is rarely useful at admission (or later if there is clinical improvement) for patients with bronchiolitis. It can increase stress and work of breathing of these acutely ill infants, which may in turn, worsen their respiratory status. ETCO₂ has shown good correlation with capillary and arterial CO₂ in both adults and children [2, 21, 26] and is especially useful for detecting trends in ventilatory status.

This study has several limitations. First, it is not a randomized controlled trial, so differences with standard oxygen therapy cannot be evaluated and compared in terms of effects on ventilation status, length of stay, or effectiveness in preventing the need for further ventilatory support. The lack of a comparison group does not allow for control of confounding factors and it may be argued that other interventions (nasal suction, use of hypertonic saline, salbutamol/adrenaline) during ED stay might have influenced our findings. However, if this had been the case, improvement of ETCO₂ and RR would have been expected between t-1 and t₀, when children received the above mentioned interventions, as opposed to the steady ETCO₂ and RR values found at these times in our study. Nevertheless, even if a significant decrease in these parameters was recorded only after HFNC start, a delayed contribution of other interventions cannot be completely excluded.

Compared to other study cohorts [14, 19, 22] our sample size mainly includes young infants under 3 months of age, who are most commonly at higher risk of moderate–severe disease because of the narrower respiratory airways, reduced respiratory reserve, and higher metabolic demands. This peculiar feature may explain the longer length of stay in our study, while no data on HFNC influence on length of stay can be drawn from our study design. A recent Spanish study [10] assessing the effects of HFNC in a similar cohort of very young patients on the ward, reported similar results in terms of duration of oxygen therapy (median of 4 days) and length of hospitalization (median of 9 days).

Finally, the small sample size of our study should be noted. However, it was designed as a pilot study and our results may provide useful data for future well-designed randomized controlled trials.

The possibility to manage infants with bronchiolitis outside the PICU has important economic implications as pediatric critical care is expensive and sometimes difficult to access. In contrast to nasal-CPAP which is often poorly tolerated and is impractical outside the intensive care setting [7, 8], HFNC provides a well-tolerated, easy to use and safe respiratory support, that should be considered for infants with moderate–severe bronchiolitis needing oxygen supplementation, hospitalized in a pediatric ward. Despite the fact that our small sample size does not allow to properly assess the safety of this intervention on the ward, possible harm related to HFNC is rare according to the published literature. So far, only one report of a significant pneumothorax requiring intubation has been reported in a 2-month-old child who was receiving HFNC at a flow of 8 l/min for bronchiolitis [13].

However, our results cannot support that HFNC can be safely introduced widely on a general pediatric ward even in centers not provided with an intensive care unit facility. In these settings, careful medical judgment based on patient’s clinical status and knowledge of the system network and pathways for deteriorating patients should always drive clinical decision making in the first place. Randomized controlled studies are needed to confirm the findings of this pilot study and to assess HFNC effect on other outcomes, such as improved enteral feeding, reduction in transfer to the intensive care unit, intubation rate, and length of hospitalization, as well as long-term benefits and economic impact for the healthcare system.

Conclusion

Use of HFNC for oxygen administration is feasible for infants with moderate–severe bronchiolitis who are hospitalized in the ward and need supplemental oxygen. HFNC therapy improves oxygen saturation levels and seems to be associated with a decrease in both ETCO₂ and RR.

Acknowledgments The authors thank Dr. Silvia Carraro for her assistance with the statistical analysis and Dr. Lisanna Tomasi and Dr.
Laura Cesca for their contribution in recruiting patients and data collection. The authors also thank the head nurses Ms. Francesca Selmin and Ms. Mariella Rubin and all the nurses for their precious support with the research project.

**Conflict of interest** Dr. Krauss is a consultant for Oridion Medical, a capnography company, and holds three patents in the area of capnography. The other authors have no conflicts of interest or funding to disclose. The authors have not received any financial support, salary, or other personal benefits by Fisher & Paykel Healthcare for the present study and do not hold stock in the company.

**Source of funding** None

### Appendix

**Bronchiolitis severity score (modified by Wang et al. [28])**

| Illness severity | Score |
|------------------|-------|
| Mild             | ≤5    |
| Moderate         | 6–10  |
| Severe           | >10   |

#### Table:

| Clinical assessment | Points |
|---------------------|--------|
| Quiet, sleeping     | 0      |
| Crying when touched, but easy to console | 1      |
| Moderately irritable, difficult to console | 2      |
| Extremely irritable, lethargic, poor feeding | 3      |
| No crepitations, no wheezing | 0      |
| Diffuse crepitations or terminal expiratory wheezing | 1      |
| Entire expiration wheezing | 2      |
| Diffuse inspiratory and expiratory wheezing | 3      |
| None               | 0      |
| Mild (intercostal retractions) | 1      |
| Moderate (tracheo-sternal retractions) | 2      |
| Severe (severe retractions with nasal flaring) | 3      |

| Respiratory rate | Points |
|------------------|--------|
| <40 bpm          | 0      |
| 40–55 bpm        | 1      |
| 56–65 bpm        | 2      |
| >65 bpm          | 3      |

| Oxygen saturation | Points |
|-------------------|--------|
| >96 %             | 0      |
| 93–95 %           | 1      |
| 90–92 %           | 2      |
| <90 %             | 3      |

**References**

1. Abboud PA, Roth PJ, Skiles CL, Stolfi A, Rowin ME (2012) Predictors of failure in infants with viral bronchiolitis treated with high-flow, high-humidity nasal cannula therapy. Pediatr Crit Care Med 13:e343–e349
2. Abramo TJ, Wiebe RA, Scott SM, Primm PA, McIntyre D, Mylder T (1996) Noninvasive capnometry in a pediatric population with respiratory emergencies. Pediatr Emerg Care 12:252–254
3. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis (2006) Diagnosis and management of bronchiolitis. Pediatrics 118:1774–1793
4. Campbell DM, Shah PS, Shah V, Kelly EN (2006) Nasal continuous positive airway pressure from high flow cannula versus infant flow for preterm infants. J Perinatol 26:546–549
5. Colman Y, Krauss B (1999) Microstream capnography technology: a new approach to an old problem. J Clin Monit Comput 15:403–409
6. Dani C, Pratesi S, Migliori C, Bertini G (2009) High flow nasal cannula therapy as respiratory support in the preterm infant. Pediatr Pulmonol 44:629–634
7. de Klerk A (2008) Humidified high-flow nasal cannula: is it the new and improved CPAP? Adv Neonatal Care 8:98–106
8. Donlan M, Fontela PS, Puligandla PS (2011) Use of continuous positive airway pressure (CPAP) in acute viral bronchiolitis: a systematic review. Pediatr Pulmonol 46:736–746
9. Dysart K, Miller TL, Wollson MR, Shaffer TH (2009) Research in high flow therapy: mechanisms of action. Respir Med 103:1400–1405
10. González Martínez F, González Sánchez MI, Rodríguez Fernández R (2013) Clinical impact of introducing ventilation with high flow oxygen in the treatment of bronchiolitis in a paediatric ward. An Pediatr (Barc) 78:210–215
11. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, Klassen TP, Vandermeer B (2011) Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ 342:d1714
12. Hasan RA, Habib RH (2011) Effects of flow rate and airleak at the nares and mouth opening on positive distending pressure delivery using commercially available high-flow nasal cannula systems: a lung model study. Pediatr Crit Care Med 12:e29–e33
13. Hedge S, Prodhan P (2013) Serious airleak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases. Pediatrics 132:e939
14. Hilliard TN, Archer N, Laura H, Heraghty J, Cottis H, Mills K, Ball S, Davis P (2012) Pilot study of vapotherm oxygen delivery in moderately severe bronchiolitis. Arch Dis Child 97:182–183
15. Holleman-Duray D, Kaupie D, Weiss MG (2007) Heated humidified high-flow nasal cannula therapy: a report of 3 cases. Pediatrics 119:1317–1319
16. Krauss B (2008) Advances in the use of capnography for nonintubated patients. Isr J Emerg Med 8:3–15
17. Lenglet H, SztrymF, Leroy C, Brun P, Dreyfuss D, Ricard JD (2012) Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy. Respir Care 57:1873–1878
18. Mandelberg A, Amirav I (2010) Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol 45:36–40
19. McKiernan C, Chua LC, Visintainer PF, Allen H (2010) High flow nasal cannulae therapy in infants with bronchiolitis. J Pediatr 156:634–638
20. Nagakumar P, Doull I (2012) Current therapy for bronchiolitis. Arch Dis Child 97:827–830
21. Plewa MC, Sikora S, Engoren M, Tome D, Thomas J, Deuster A (1995) Evaluation of capnography in nonintubated emergency
22. Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL (2011) Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med 37:847–852

23. Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children. NHS Quality improvement Scotland. Available at www.sign.ac.uk. Accessed 30 May 2012

24. Shoemaker MT, Pierce MR, Yoder BA, Di Geronimo RJ (2007) High flow nasal cannula versus nasal CPAP for neonatal respiratory disease: a retrospective study. J Perinatol 27:85–91

25. Sreenan C, Lemke RP, Hudson-Mason A, Ostovich H (2001) High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. Pediatrics 107:1081–1083

26. Trevisanuto D, Giuliotto S, Cavallin F, Doglioni N, Toniazzo S, Zanardo V (2012) End-tidal carbon dioxide monitoring in very low birth weight infants: correlation and agreement with arterial carbon dioxide. Pediatr Pulmonol 47:367–372

27. Walsh M, Engle W, Laptook A, Kazzi SN, Buchter S, Rasmussen M, Yao Q, National Institute of Child Health and Human Development Neonatal Research Network (2005) Oxygen delivery through nasal cannulae to preterm infants: can practice be improved? Pediatrics 116:857–861

28. Wang EE, Milner RA, Navas L, Maj H (1992) Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis 145:106–109

29. Wilkinson D, Andersen C, O’Donnell CP, De Paoli AG (2011) High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev. 5:CD006405

30. Wing R, James C, Maranda LS, Armsby CC (2012) Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatr Emerg Care 28:1117–1123

31. Woodhead DD, Lambert DK, Clark JM, Christensen RD (2006) Comparing two methods of delivering high-flow gas therapy by nasal cannula following endotracheal extubation: a prospective, randomized, masked, crossover trial. J Perinatol 26:481–485

32. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP (2011) Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev.;(4):CD006458

33. Zorc JJ, Hall CB (2010) Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 125:342–349